Concomitant psychotropic medication for youths

American Journal of Psychiatry

Volumn 160, Issue 3, 2003, Pages 438-449

  Safer, Daniel J ^a   Zito, Julie Magno ^a   DosReis, Susan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOTROPIC AGENT; METHYLPHENIDATE;

ADJUSTMENT DISORDER; AGGRESSION; BEHAVIOR; COMMUNITY; DATA ANALYSIS; EMOTIONAL DISORDER; GENDER; HOSPITAL PATIENT; HUMAN; JUVENILE; MEDICAL PRACTICE; MEDLINE; MENTAL HEALTH; PATIENT; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIST; REVIEW; SOCIAL ASPECT; ADOLESCENT; AGE; CHILD; CLINICAL PRACTICE; COMMUNITY MENTAL HEALTH CENTER; COMPARATIVE STUDY; DRUG COMBINATION; DRUG UTILIZATION; FEMALE; HOSPITALIZATION; MALE; MEDICAL AUDIT; MENTAL DISEASE; RISK FACTOR; STATISTICS;

ADOLESCENT; AGE FACTORS; CHILD; COMMUNITY MENTAL HEALTH CENTERS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; HOSPITALIZATION; HUMANS; MALE; MEDICAL AUDIT; MENTAL DISORDERS; METHYLPHENIDATE; PHYSICIAN'S PRACTICE PATTERNS; PSYCHOTROPIC DRUGS; RISK FACTORS;

EID: 0037365656     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.160.3.438     Document Type: Review

References (150)

1. Rittmannsberger H, Meise U, Schauflinger K, Horvath E, Donat H, Hinterhuber H: Polypharmacy in psychiatric treatment: patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry 1999; 14:33-40
2. Tyrer P: Drug treatment of psychiatric patients in general practice. Br Med J 1978; 2:1008-1010
3. Baldessarini RJ, Kando JC, Centorrino F: Hospital use of antipsychotic agents in 1989 and 1993: stable dosing with decreased length of stay. Am J Psychiatry 1995; 152:1038-1044
4. Frye MA, Ketter TA, Leverich GS, Huggins T, Lantz C, Denicoff KD, Post RM: The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000; 61:9-15
5. Foote SM, Etheredge L: Increasing use of new prescription drugs: a case study. Health Affairs 2000; 19:165-170
6. Zuvekas SH: Trends in mental health services use and spending, 1987-1996. Health Affairs 2001; 20:214-224
7. Colley CA, Lucas LM: Polypharmacy: the cure becomes the disease. J Gen Intern Med 1993; 8:278-283
8. Nichol MB, Stimmel GL, Lange SC: Factors predicting the use of multiple psychotropic medications. J Clin Psychiatry 1995; 56:60-66
9. Safer DJ: Changing patterns of psychotropic medication prescribed by child psychiatrists in the 1990's. J Child Adolesc Psychopharmacol 1997; 7:267-273
10. Rushton JL, Whitmire JT: Pediatric stimulant and SSRI prescription trends: 1992-1998. Arch Pediatr Adolesc Med 2001; 155:560-565
11. Olfson M, Marcus SC, Weissman MW, Jensen PS: National trends in the use of psychotropic medication by children. J Am Acad Child Adolesc Psychiatry 2002; 41:514-521
12. Graham P, Turk J, Verhulst FC: Child Psychiatry, 3rd ed. Oxford, UK, Oxford University Press, 1999
13. Kutcher SP: Child and Adolescent Psychopharmacology. Philadelphia, WB Saunders, 1997
14. VVeiner JM: Textbook of Child and Adolescent Psychiatry, 2nd ed. Washington, DC, American Psychiatric Press and American Academy of Child and Adolescent Psychiatry, 1997
15. Barker P: Basic Child Psychiatry, 6th ed. Oxford, UK, Blackwell Science, 1995
16. Green WH: Child and Adolescent Clinical Psychopharmacology. Baltimore, Williams & Wilkins, 1995
17. Jensen PS, Bhatara VS, Vitiello B, Hoagwood K, Feil M, Burke LB: Psychoactive medication prescribing practices for US children: gaps between research and clinical practice. J Am Acad Child Adolesc Psychiatry 1999; 38:557-565
18. Levine J: Ascertainment of side effects in psychopharmacologic clinical trials, in Methodology of the Evaluation of Psychotropic Drugs. Edited by Benton O, Maier W, Rickels K. Heidelburg, Germany, Springer-Verlag, 1990, pp 130-135
19. Bhatara VS, Feil M, Hoagwood K, Vitiello B, Zima B: Trends in combined pharmacotherapy with stimulants for children. Psychiatr Serv 2002; 53:244
20. Schirm E, Tobi H, Zito JM, deJong-van den Berg L: Psychotropic medication in children: a study from the Netherlands. Pediatrics 2001; 108:e25
21. Rappley MD, Mullan PB, Alvarcz FJ, Eneli IU, Wang J, Gardiner JC: Diagnosis of attention-deficit/hyperactivity disorder and use of psychotropic medication in very young children. Arch Pediatr Adolesc Med 1999; 153:1039-1045
22. Ghuman JK, Ginsberg GS, Subramaniam G, Ghuman HS, Kau AS, Riddle MA: Psychostimulants in preschool children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2001; 40:516-524
23. Boles M, Lynch FL, DeBar LL: Variations in pharmacotherapy for attention deficit hyperactivity disorder in managed care. J Child Adolesc Psychopharmacol 2001; 11:43-52
24. Zarin DA, Suarez AP, Pincus HA, Kupersanin BA, Zito JM: Clinical and treatment characteristics of children with attention deficit/ hyperactivity disorder in psychiatric practice. J Am Acad Child Adolesc Psychiatry 1998; 37:1262-1270
25. Wilens TE, Biederman J, Geist DE, Steingard R, Spencer T: Nortriptyline in the treatment of ADHD: a chart review of 58 cases. J Am Acad Child Adolesc Psychiatry 1993; 32:343-349
26. Geller DA, Biederman J, Reed ED, Spencer T, Wilens TE: Similarities in response to fluoxetine in the treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1995; 34:36-44
27. Cohen LG, Biederman J, Gibson S, Whitt S, Frazier J, Wozniak J, Wilens TE, Spencer T, Mick E: Pharmacotherapy of attention deficit hyperactivity disorder (ADHD) in psychiatrically referred girls, in Abstracts of the 39th New Clinical Drug Evaluation Unit Meeting. Bethesda, Md, National Institute of Mental Health, 1999
28. Biederman J, Mick E, Bostic JQ, Prince J, Daly J, Wilens TE, Spencer T, Garcia-Jetton J, Russell R, Wozniak J, Faraone SV: The naturalistic course of pharmacologic treatment of children with maniclike symptoms: a systematic chart review. J Clin Psychiatry 1998; 59:628-637
29. Kumra S, Frazier JA, Jacobsen LK, McKenna K, Gordon CT, Lenane MC, Hamburger SD, Smith AK, Albus KE, Alaghband-Rad J, Rapoport JL: Childhood-onset schizophrenia. Arch Gen Psychiatry 1996; 53:1090-1097
30. Martin A, Scahill L, Klin A, Volkmar FR: Higher-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use. J Am Acad Child Adolesc Psychiatry 1999; 38:923-931
31. Aman MG, Van Bourgondien ME, Wolford PL, Sarphane G: Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use. J Am Acad Child Adolesc Psychiatry 1995; 34:1672-1681
32. Kaplan SL, Simms RM, Busner J: Prescribing practices of outpatient child psychiatrists. J Am Acad Child Adolesc Psychiatry 1994; 33:35-44
33. Storch DD: Outpatient pharmacotherapy in a community mental health center. J Am Acad Child Adolesc Psychiatry 1998; 37:249-250
34. Ahsanuddin KM, Ivey JA, Schlotzhauer D, Hall K, Prosen H: Psychotropic medication prescription patterns in 100 hospitalized children and adolescents. J Am Acad Child Psychiatry 1983; 22:361-364
35. Kaplan SL, Busner J: Prescribing practices of inpatient child psychiatrists under three auspices of care. J Child Adolesc Psychopharmacol 1997; 7:275-286
36. Bhatara V, Feil M, Hoagwood K, Vitiello B, Zima BT: Concomitant pharmacotherapy in youths receiving antidepressants or stimulants: national trends, in Abstracts of Posters Presented at the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Washington, DC, AACAP, 2000
37. Hussain MZ, Chaudry ZA, Hussain S: Evaluation and intervention of prodromal symptoms of bipolar disorder, in Abstracts of the 41st New Clinical Drug Evaluation Unit Meeting, Bethesda, Md, National Institute of Mental Health, 2001
38. Baumgartner JL, Emslie GJ, Crismon ML: Citalopram use in 17 children and adolescents: a case series. Abstracts of the 41st New Clinical Drug Evaluation Unit Meeting. Ibid
39. Cohen LG, Doyle RL, Prince JB, Wozniak J, Wilens TE, Spencer TJ, Biederman J: Pharmacoepidemiology of citalopram in youth with mood disorders. Abstracts of the 41st New Clinical Drug Evaluation Unit Meeting. Ibid
40. Zito JM, Safer DJ, dosReis S, Gardner JF, Magder L, Soeken K, Boles M, Lynch F, Riddle MAM: Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med 2003; 57:17-25
41. Patel NC, Sanchez RJ, Johnsrud MT, Crismon ML: Trends in antipsychotic use in a Texas Medicaid population of children and adolescents: 1996 to 2000. J Child Adolesc Psychopharmacol 2002; 12:221-229
42. Malone RP, Sheikh R, Zito JM: Novel antipsychotic medications in the treatment of children and adolescents. Psychiatr Serv 1999; 50:171-174
43. Epstein MA, Shaywitz SE, Shaywitz BA, Woolston JL: The boundaries of attention deficit disorder. J Learn Disabil 1991; 24:78-86
44. Bussing R, Zima BT, Belin T: Variations in ADHD treatment among special education students. J Am Acad Child Adolesc Psychiatry 1998; 37:968-976
45. Mattison RE: Use of psychotropic medications in special education students with serious emotional disturbance. J Child Adolesc Psychopharmacol 1999; 9:149-155
46. Zima BT, Bussing R, Crecelius GM, Kaufman A, Belin TR: Psychotropic medication treatment patterns among school-aged children in foster care. J Child Adolesc Psychopharmacol 1999; 9:135-147
47. Anderson TR, Naylor M, Kruesi M, Stoewe J: Co-pharmacy and polypharmacy in children and adolescents in substitute care. Abstracts of the 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Washington, DC, AA-CAP, 2002
48. Connor DF, Ozbayrak KR, Harrison RJ, Melloni RH: Prevalence and patterns of psychotropic and anticonvulsant medication use in children and adolescents referred to residential treatment. J Child Adolesc Psychopharmacol 1998; 8:27-38
49. Hogg J: The administration of psychotropic and anticonvulsant drugs to children with profound intellectual disability and multiple impairments. J Intellect Disabil Res 1992; 36:473-488
50. Wilens TE, Biederman J, Spencer T: Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1994; 33:424-427
51. Prince JB, Wilens TE, Biederman J, Spencer TJ, Wozniak JR: Clonidine for sleep disturbances associated with attention deficit hyperactivity disorder: a systematic chart review of 62 cases. J Am Acad Child Adolesc Psychiatry 1996; 35:599-605
52. Hill P: The hyperactive child, in Difficult Clinical Problems in Psychiatry. Edited by Lader M, Naber D. London, Martin Dunitz, 1999, pp 213-228
53. Swanson JM, Connor DF, Cantwell D: Combining methylphenidate and clonidine: ill-advised. J Am Acad Child Adolesc Psychiatry 1999; 38:617-619
54. Rappley MD, Eneli IU, Mullan PB, Alvarez FJ, Wang J, Luo Z, Gardiner JC: Patterns of psychotropic medication use in very young children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr 2002; 23:23-30
55. Pathiyal A, Miwa LJ, Sverdiov LS, Gardner E, Jones JK: Patterns of methylphenidate use, in Abstracts of the 1998 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. Alexandria, Va, ASCPT, 1998
56. Zito JM, Safer DJ, dosReis S, Gardner JF, Soeken K, Boles M, Lynch F: The rising prevalence of antidepressants among US youths. Pediatrics 2002; 109:721-727
57. Minter RE, Mandel MR: The treatment of psychotic major depressive disorder with drugs and electroconvulsive therapy. J Nerv Ment Dis 1979; 167:726-733
58. Dufresne RL: Issues in polypharmacotherapy: focus on major depression. Psychopharmacol Bull 1996; 32:547-553
59. Freeman MP, Stoll AL: Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry 1998; 155:12-21
60. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH: A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000; 57:794-801
61. Carlson GA, Rapport MD, Kelly KL, Pataki CS: Methylphenidate and desipramine in hospitalized children with comorbid behavior and mood disorders: separate and combined effects on behavior and mood. J Child Adolesc Psychopharmacol 1995; 5:191-204
62. Rapport MD, Carlson GA, Kelly KL, Pataki C: Methylphenidate and desipramine in hospitalized children, I: separate and combined effects on cognitive function. J Am Acad Child Adolesc Psychiatry 1993; 32:333-342
63. Pataki CS, Carlson GA, Kelly KL, Rapport MD, Biancaniello TM: Side effects of methylphenidate and desipramine alone and in combination in children. J Am Acad Child Adolesc Psychiatry 1993; 32:1065-1072
64. Gittelman-Klein R, Klein DF, Katz S, Saraf K, Pollack E: Comparative effects of methylphenidate and thioridazine in hyperkinetic children, I: clinical results. Arch Gen Psychiatry 1976; 33:1217-1231
65. Connor DF, Barkley RA, Davis HT: A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr 2000; 39:15-25
66. Kurlan R (Tourette's Syndrome Study Group): Treatment of ADHD in children with tics. Neurology 2002; 58:527-536
67. Turgay A, Binder C, Snyder R, Fisman S: Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 2002; 110:e34
68. Carlson GA, Rapport MD, Kelly KL, Pataki CS: The effects of methylphenidate and lithium on attention and activity level. J Am Acad Child Adolesc Psychiatry 1992; 31:262-270
69. Bess A, Cunningham S: Important Drug Warning Regarding Mellaril: Letter to Physicians. East Hanover, NJ, Novartis Pharmaceutical Corp, 2000
70. Riddle MA, Geller B, Ryan N: Another sudden death in a child treated with desipramine. J Am Acad Child Adolesc Psychiatry 1994; 32:792-797
71. Elia J, Borcherding BG, Rapoport JL, Keysor CS: Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res 1991; 36:141-155
72. Hussain MZ, Zubaido A, Chaudhry MB: Novel antipsychotic in ADHD with conduct disorder, in 2000 Annual Meeting Syllabus and Proceedings Summary. Washington, DC, American Psychiatric Association, 2000
73. Steingard RJ, Goldberg M, Lee D, DeMaso DR: Adjunctive clonazepam treatment of tic symptoms in children with comorbid tic disorders and ADHD. J Am Acad Child Adolesc Psychiatry 1994; 33:394-399
74. Saccomani L, Rizzo P, Nobili L: Combined treatment with haloperidol and trazodone in patients with tic disorders. J Child Adolesc Psychopharmacol 2000; 10:307-310
75. Figueroa Y, Rosenberg DR, Birmaher B, Keshavan MS: Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents. J Child Adolesc Psychopharmacol 1998; 8:61-67
76. Kowatch RA, Suppes T, Gilfillan SK, Fuentes RM, Grannemann BD, Emslie GJ: Clozapine treatment of children and adolescents with bipolar disorder and schizophrenia. J Child Adolesc Psychopharmacol 1995; 5:241-253
77. Fitzgerald KD, Stewart CM, Tawile V, Rosenberg DR: Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder. J Child Adolesc Psychopharmacol 1999; 9:115-123
78. Strober M, Freeman R, Rigali J, Schmidt S, Diamond R: The pharmacotherapy of depressive illness in adolescence, II: effects of lithium augmentation in nonresponders to imipramine. J Am Acad Child Adolesc Psychiatry 1992; 31:16-20
79. Brown RP, Ingber PS, Tross S: Pemoline and lithium in a patient with attention deficit disorder. J Clin Psychiatry 1983; 44:146-148
80. Chang KD, Ketter TA: Mood stabilizer augmentation with olanzapine in acutely manic children. J Child Adolesc Psychopharmacol 2000; 10:45-49
81. Ryan ND, Meyer V, Dachille S, Mazzie D, Puig-Antich J: Lithium antidepressant augmentation in TCA-refractory depression in adolescents. J Am Acad Child Adolesc Psychiatry 1988; 27:371-376
82. Simeon JG, Dinicolo VF, Ferguson HB, Copping W: Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up. Prog Neuropsychopharmcol Biol Psychiatry 1990; 14:791-795
83. Bussing R, Levin GM: Methamphetamine and fluoxetine treatment of a child with attention deficit hyperactivity disorder and obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 1993; 3:53-58
84. Gammon GD, Brown TE: Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharmacol 1991; 3:1-10
85. Parraga HC, Kelly DP, Parraga MI, Cochran MK, Maxim LT: Combined psychostimulant and tricyclic antidepressant treatment of Tourette's syndrome and comorbid disorders in children. J Child Adolesc Psychopharmacol 1994; 4:113-122
86. Findling RL: Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series. J Child Adolesc Psychopharmacol 1996; 6:165-175
87. Hawkridge S, Stein DJ, Bouwer C: Combined pharmacotherapy for TS and OCD (letter). J Am Acad Child Adolesc Psychiatry 1996; 35:703-704
88. Licamele VVL, Goldberg RL: The concurrent use of lithium and methylphenidate in a child. J Am Acad Child Adolesc Psychiatry 1989; 28:785-787
89. Sallee FR, DeVane CL, Ferrell RE: Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J Child Adolesc Psychopharmacol 2000; 10:27-34
90. Preda A, Madlener A, Hetherington P: Premature polypsychopharmacology. J Am Acad Child Adolesc Psychiatry 1998; 37:348-349
91. Budman CL, Sherling M, Bruun RD: Combined pharmacotherapy risk. J Am Acad Child Adolesc Psychiatry 1995; 34:263-264
92. Levy F, Einfeld S, Looi J: Combined pharmacotherapy or polypharmacy? J Paediatr Child Health 1996; 32:265-266
93. Fisman S, Reniers D, Diaz P: Erythromycin interaction with risperidone or clomipramine in an adolescent. J Child Adolesc Psychopharmacol 1996; 6:133-138
94. Gara L, Roberts W: Adverse response to methylphenidate in combination with valproic acid. J Child Adolesc Psychopharmacol 2000; 10:39-43
95. Bhatara VS, Kallepalli BR, Misra LK, Awadallah S: A possible clonidine-trazodone-dextroamphetamine interaction in a 12-year-old boy. J Child Adolesc Psychopharmacol 1996; 6:203-209
96. Fenichel RR: Combining methylphenidate and clonidine: the role of post-marketing surveillance. J Child Adolesc Psychopharmacol 1995; 5:155-156
97. DeMaso DR, Hunter TA: Combining fluoxetine with desipramine (letter). J Am Acad Child Adolesc Psychiatry 1990; 29:151
98. Chiu S, Welch C, Corwin RD, Ziegler J, Sachs H: Symptomatic electrocardiography changes from combining olanzapine, divalproex sodium and antidepressants, in Abstracts of the 46th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Washington, DC, AACAP, 1999
99. Vitiello B, Jensen PS: Medication development and testing in children and adolescents: current problems, future directions. Arch Gen Psychiatry 1997; 54:871-876
100. Wagner KD: Polypharmacy for children. Psychiatr Times, Nov 2000, pp 78-79
101. Council of the American Academy of Child and Adolescent Psychiatry: Policy statement: prescribing psychoactive medications for children and adolescents. MCAP News, July 2000, p 207
102. Behr R: Overzealous prescribing of medications. J Am Acad Child Adolesc Psychiatry 1998; 37:900-901
103. Fattinger K, Roos M, Vergeres P, Holenstein C, Kind B, Masche U, Stocker DN, Braunschweig S, Kullak-Ublick GA, Galeazzi RL, Follath F, Gasser T, Meier PJ: Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol 2000; 49:158-167
104. Martinez-Mir I, Garcia-Lopez M, Palop V, Ferrer JM, Rubio E, Morales-Olivas FJ: A prospective study of adverse drug reactions in hospitalized children. Br J Clin Pharmacol 1999; 47:681-688
105. Turner S, Nunn AJ, Fielding K, Choonara I: Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 1999; 88:965-968
106. Geller B, Cooper TB, Farooki ZQ, Chestnut EC: Dose and plasma levels of nortriptyline and chlorpromazine in delusionally depressed adolescents and of nortriptyline in nondelusionally depressed adolescents. AmJ Psychiatry 1985; 142:336-338
107. Ambrosini PJ, Sheikh RM: Increased plasma valproate concentrations when coadministered with guanfacine. J Child Adolesc Psychopharmacol 1998; 8:143-147
108. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB: Valproic acid hepatic fatalities: a retrospective review. Neurology 1987; 37:379-385
109. Ghose K: The need for a review journal of drug use and the elderly. Drugs Aging 1991; 1:2-5
110. McMillan DA, Harrison PM, Rogers LJ, Tong N, McLean AJ: Polypharmacy in an Australian teaching hospital: preliminary analysis of prevalence, types of drugs and associations. Med J Aust 1986; 145:339-342
111. Hack S, Chow B: Pediatric psychotropic medication compliance. J Child Adolesc Psychopharmacol 2001; 11:59-67
112. Bjerrum L, Sogaard J, Hallas J, Kragstrup J: Polypharmacy: correlations with sex, age and drug regimen. Eur J Clin Pharmacol 1998; 54:197-202
113. Pliszka SR, Carlson CL, Swanson JM: ADHD With Comorbid Disorders. New York, Guilford, 1999
114. Werry JS: Introduction, in Practitioner's Guide to Psychoactive Drugs for Children and Adolescents, 2nd ed. Edited by Werry JS, Aman MG. New York, Plenum, 1999, pp 3-22
115. Klein RG, Abikoff H, Klass E, Ganeles D, Seese LM, Pollack S: Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Arch Gen Psychiatry 1997; 54:1073-1080
116. Spencer T, Biederman J, Kerman K, Steingard R, Wilens TE: Desipramine treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1993; 32:354-360
117. Steingard R, Biederman J, Spencer T, Wilens TE, Gonzalez A: Comparison of clonidine response in the treatment of attention-deficit hyperactivity disorder with and without comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 1993; 32:350-353
118. Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E, Arnsten AFT, Cohen DJ, Leckman JF: A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001; 158:1067-1074
119. Kingsbury SJ, Yi D, Simpson GM: Rational and irrational polypharmacy. Psychiatr Serv 2001; 52:1033-1036
120. Preskorn SH, Lacey RL: Polypharmacy: when is it rational? J Prac Psychiatr Behav Health 1995; 1:92-98
121. Biederman J: Attention-deficit/hyperactivity disorder: a lifespan perspective. J Clin Psychiatry 1998; 59:4-16
122. Popper C: Balancing knowledge and judgment. Child Adolesc Psychiatr Clin North Am 1995; 4:483-523
123. Carlson GA, Ranade L, Qadir A: Management of psychopharmacologic agents in children and adolescents. Psychiatr Q 1992; 63:391-411
124. King RA: Practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1998; 37:27S-45S
125. Emslie GJ, Mayes TL, Hughes CW: Updates in the pharmacologic treatment of childhood depression. Psychiatr Clin North Am 2000; 23:813-835
126. Theesen KA: The Handbook of Psychiatric Drug Therapy for Children and Adolescents. New York, Pharmaceutical Products Press, 1995
127. Wilens TE, Spencer T, Biederman J, VVozniak J, Connor DF: Combined pharmacotherapy: an emerging trend in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 1995; 34:110-112
128. Rapoport JL: An evidence-based approach to pediatric psychiatry in 2001 Annual Meeting Syllabus and Proceedings Summary. Washington, DC, American Psychiatric Association, 2001
129. Dalton R, Forman MA: Psychiatric Hospitalization for School-Age Children. Washington, DC, American Psychiatric Press, 1992
130. Safer DJ: An outpatient/inpatient comparison of child psychiatric diagnosis. Am J Orthopsychiatry 1995; 65:298-303
131. Aronet ET, Noam CG, Weinstein SR: Structured diagnostic interviews and clinicians' discharge diagnoses in hospitalized adolescents. J Am Acad Child Adoles Psychiatry 1993; 32:674-681
132. Connor DF, Ozbyrak KR, Kusiak KA, Caponi AB, Melloni RH: Combined pharmacotherapy in children and adolescents in a residential treatment center. J Am Acad Child Adolesc Psychiatry 1997; 36:248-254
133. Weller E, Rowan A, Elia J, Weller R: Aggressive behavior in patients with attention-deficit/hyperactivity disorder, conduct disorder, and pervasive developmental disorders. J Clin Psychiatry 1999; 60:5-11
134. Green WH: Principles of psychopharmacology and specific drug treatments, in Child and Adolescent Psychiatry, 2nd ed. Edited by Lewis M. Baltimore, Williams & Wilkins, 1996, pp 772-801
135. Kutcher S: Practical clinical issues regarding child and adolescent psychopharmacology. Child Adolesc Psychiatr Clin North Am 2000; 9:245-260
136. Sanchez L, Hagino O, Weller E, Weller R: Bipolarity in children. Psychiatr Clin North Am 1999; 22:629-648
137. Vitiello B, Jensen PS: Developmental perspectives in pediatric psychopharmacology. Psychopharmacol Bull 1995; 31:75-81
138. Milin RP, Simeon J, Spenst BA: Double-blind study of paroxetine in adolescents with unipolar major depression, in Abstracts of the 46th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Washington, DC, AACAP, 1999
139. Guyatt GH, Jaeschke R, Roberts R: N-of-1 randomized clinical trials in pharmacoepidemiology, in Pharmacoepidemiology, 3rd ed. Edited by Strom BL. Chichester, UK, John Wiley & Sons, 2000, pp 615-632
140. Kent MA, Camfield CS, Camfield PR: Double-blind meth ylphenidate trials. Arch Pediatr Adolesc Med 1999; 153:1291-1296
141. Field CJ, Aman MG, White AJ, Vaithianathan C: A single-subject study of imipramine in a mentally retarded woman with depressive symptoms. J Ment Defic Res 1986; 30:191-198
142. Woosley R: Opportunities in phase IV to improve drug development. Food Drug Law J 1997; 52:185-188
143. Nelson R: We need a postmarketing drug development process. Pharmacoepidemiol Drug Saf 2000; 9:253-255
144. Jallon P: The problem of intractability: the continuing need for new medical therapies in epilepsy. Epilepsia 1997; 38:S37-S42
145. Zanchetti A, Hansson L: Introduction: the role of combination therapy in modern antihypertensive therapy. J Cardiovasc Pharmacol 2000; 35(suppl 3):S1
146. Gulick RM, Mellors JW, Havur D, Eron JJ, Gonzalez C, McMahon D: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-739
147. de Girolamo G, Williams P, Cappiello V: Psychotropic drug utilization and audit in two Italian psychiatric services. Psychol Med 1987; 17:989-997
148. Meyer TJ, Van Kooten D, Marsh S, Prochazka AV: Reduction of polypharmacy by feedback to clinicians. J Gen Intern Med 1991; 6:133-136
149. Pitkala KH, Strandberg TE, Tilvis RS: Is it possible to reduce polypharmacy in the elderly? a randomized, controlled trial. Drugs Aging 2001; 18:143-149
150. Woolston JL: Combined pharmacotherapy: pitfalls of treatment. J Am Acad Child Adolesc Psychiatry 1999; 38:1455-1457